港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌_老虎社区_美港股上老虎

港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌

智通财经03-17

重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作商业化目标累计销售...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2620241656?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-17 09:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620241656","market":"fut","top_or_hot":-1,"title":"港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌","media":"智通财经","content":"<div>\n<p>重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414674.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 09:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1414674.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414674.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1414674.html","article_id":"2620241656","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620241656","pubTimestamp":1773709477,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售规","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","06688":"蚂蚁集团","01276":"恒瑞医药","BK1515":"抗疫概念","BK1606":"中医药概念","BK1147":"投资银行业与经纪业","BK4585":"ETF&股票定投概念","LU0359201612.USD":"贝莱德中国基金A2","01428":"耀才证券金融","BK1197":"保健护理产品经销商","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","02696":"复宏汉霖","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK1521":"挪威政府全球养老基金持仓","00874":"白云山","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","02565":"派格生物医药-B","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK1191":"制药","BK1161":"生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"Hong Kong Stock Announcement Nuggets | Ant Group's offer to acquire Yaocai Securities Finance has been approved to resume trading on March 17th","themeId":"808c1f0b8ebd0042a82fe4057566a434","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":0.9,"02565":0.9,"VXUS":1.5,"01428":1.5,"02696":0.9,"06688":1.5,"00874":0.9},"content_text":"重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售规模超过100亿元并获得约1.4亿港元权益金石药集团(01093)：高选择性PDE4B抑制剂(SYH2059吸入粉雾剂)在中国获临床试验批准蚂蚁集团收购耀才证券金融(01428)的要约已获批准 3月17日复牌经营业绩：中国利郎(01234)发布年度业绩 股东应占利润5.02亿元 同比增加9%丘钛科技(01478)发布年度业绩 股东应占溢利14.94亿元 同比增加435.22%建滔集团(00148)发布年度业绩 股东应占溢利44.02亿港元 同比增加169.98%周生生(00116)预计2025年度来自持续经营业务的股东应占溢利约16亿至17亿港元零跑汽车(09863)2025年净利达5.4亿元 连续两年销量翻倍中石化油服(01033)公布2025年业绩 归母净利约6.59亿元，同比增长4.3%康哲药业(00867)公布2025年业绩 拥有人应占溢利约14.89亿元 同比减少8.08%","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}